For U.S. Healthcare Professionals only
Indications
INDICATIONS
AUGTYRO® (repotrectinib) is indicated for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC).
AUGTYRO® (repotrectinib) is indicated for the treatment of adult and pediatric patients 12 years of age and older with solid tumors that:
This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trial(s).
U.S. Full Prescribing Information
Patient Information
Patient Site
REQUEST A REP